134872-23-4|2-Bromo-5-(methylthio)pyridine| Ambeed

Structure of 134872-23-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

{[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

Quality Control of [ 134872-23-4 ] Purity: 96% SDS Specification

COA

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

NMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

CNMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

HPLC

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

LC-MS

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

1-2 Day Shipping
High Quality
Technical Support

Product Details of [ 134872-23-4 ]

CAS No. :	134872-23-4
Formula :	C₆H₆BrNS
M.W :	204.09
SMILES Code :	CSC1=CN=C(Br)C=C1
MDL No. :	MFCD04974522
InChI Key :	IFMCOWPTUPYFCT-UHFFFAOYSA-N
Pubchem ID :	11658494

Safety of [ 134872-23-4 ]

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H315-H319-H335
Precautionary Statements:	P280-P301+P312+P330-P304+P340+P312-P305+P351+P338-P337+P313

Computational Chemistry of [ 134872-23-4 ] Show Less

Physicochemical Properties

Num. heavy atoms	9
Num. arom. heavy atoms	6
Fraction Csp3	0.17
Num. rotatable bonds	1
Num. H-bond acceptors	1.0
Num. H-bond donors	0.0
Molar Refractivity	43.66
TPSA ? Topological Polar Surface Area: Calculated from Ertl P. et al. 2000 J. Med. Chem.	38.19 Å²

Lipophilicity

Log P_o/w (iLOGP)? iLOGP: in-house physics-based method implemented from Daina A et al. 2014 J. Chem. Inf. Model.	2.09
Log P_o/w (XLOGP3)? XLOGP3: Atomistic and knowledge-based method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry	2.39
Log P_o/w (WLOGP)? WLOGP: Atomistic method implemented from Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.	2.57
Log P_o/w (MLOGP)? MLOGP: Topological method implemented from Moriguchi I. et al. 1992 Chem. Pharm. Bull. Moriguchi I. et al. 1994 Chem. Pharm. Bull. Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.	1.85
Log P_o/w (SILICOS-IT)? SILICOS-IT: Hybrid fragmental/topological method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	2.6
Consensus Log P_o/w? Consensus Log P_o/w: Average of all five predictions	2.3

Water Solubility

Log S (ESOL):? ESOL: Topological method implemented from Delaney JS. 2004 J. Chem. Inf. Model.	-3.04
Solubility	0.187 mg/ml ; 0.000915 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble
Log S (Ali)? Ali: Topological method implemented from Ali J. et al. 2012 J. Chem. Inf. Model.	-2.83
Solubility	0.3 mg/ml ; 0.00147 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble
Log S (SILICOS-IT)? SILICOS-IT: Fragmental method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	-3.38
Solubility	0.0851 mg/ml ; 0.000417 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble

Pharmacokinetics

GI absorption? Gatrointestinal absorption: according to the white of the BOILED-Egg	High
BBB permeant? BBB permeation: according to the yolk of the BOILED-Egg	Yes
P-gp substrate? P-glycoprotein substrate: SVM model built on 1033 molecules (training set) and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94	No
CYP1A2 inhibitor? Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91	Yes
CYP2C19 inhibitor? Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86 External: ACC=0.80 / AUC=0.87	No
CYP2C9 inhibitor? Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set) and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85 External: ACC=0.71 / AUC=0.81	No
CYP2D6 inhibitor? Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set) and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87	No
CYP3A4 inhibitor? Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set) and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86	No
Log Kp (skin permeation)? Skin permeation: QSPR model implemented from Potts RO and Guy RH. 1992 Pharm. Res.	-5.85 cm/s

Druglikeness

Lipinski? Lipinski (Pfizer) filter: implemented from Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500 MLOGP ≤ 4.15 N or O ≤ 10 NH or OH ≤ 5	0.0
Ghose? Ghose filter: implemented from Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480 -0.4 ≤ WLOGP ≤ 5.6 40 ≤ MR ≤ 130 20 ≤ atoms ≤ 70	None
Veber? Veber (GSK) filter: implemented from Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10 TPSA ≤ 140	0.0
Egan? Egan (Pharmacia) filter: implemented from Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88 TPSA ≤ 131.6	0.0
Muegge? Muegge (Bayer) filter: implemented from Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600 -2 ≤ XLOGP ≤ 5 TPSA ≤ 150 Num. rings ≤ 7 Num. carbon > 4 Num. heteroatoms > 1 Num. rotatable bonds ≤ 15 H-bond acc. ≤ 10 H-bond don. ≤ 5	0.0
Bioavailability Score? Abbott Bioavailability Score: Probability of F > 10% in rat implemented from Martin YC. 2005 J. Med. Chem.	0.55

Medicinal Chemistry

PAINS? Pan Assay Interference Structures: implemented from Baell JB. & Holloway GA. 2010 J. Med. Chem.	0.0 alert
Brenk? Structural Alert: implemented from Brenk R. et al. 2008 ChemMedChem	1.0 alert: heavy_metal
Leadlikeness? Leadlikeness: implemented from Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350 XLOGP ≤ 3.5 Num. rotatable bonds ≤ 7	No; 1 violation:MW<1.0
Synthetic accessibility? Synthetic accessibility score: from 1 (very easy) to 10 (very difficult) based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties, trained on 12'782'590 molecules and tested on 40 external molecules (r² = 0.94)	2.19

Application In Synthesis of [ 134872-23-4 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 134872-23-4 ]

[ 134872-23-4 ] Synthesis Path-Downstream 1~34

1
[ 74-99-7 ]
[ 134872-23-4 ]
[ 472962-40-6 ]

References: [1]Tetrahedron,2002,vol. 58,p. 6413 - 6432.

2
[ 624-28-2 ]
[ 624-92-0 ]
[ 134872-23-4 ]

Yield	Reaction Conditions	Operation in experiment
94%	With hydrogenchloride; n-butyllithium; In hexane;	5-Methylthio-2-bromopyridine. (step 1) To a solution of 2,5-dibromopyridine (23.4 g, 0.099 mol) in ether (500 mL), n-butyl lithium (1.52 M in n-hexane, 68 mL, 0.10 mmol) was added dropwise at -78 C. and the mixture was stirred for 1 hour at the temperature. Dimethyldisulfide (9.8 mL, 0.11 mol) was added slowly at -78 C. and the mixture was stirred for 1 hour at that temperature and further 1 hour at 0 C. The mixture was quenched with aqueous 1 N hydrochloric acid (200 mL) and extracted with ether (100 mL*2), dried over magnesium sulfate (MgSO4), and concentrated in vacuo gave the title compound (18.9 g, 94%). 1H-NMR (CDCl3) δ: 8.24 (dd, J=0.8, 2.5 Hz, 1H), 7.43 (dd, J =2.8, 8.4 Hz, 1H), 7.38 (dd, J =0.8, 8.4 Hz, 1H), 2.50 (s, 3H).
94%	With hydrogenchloride; n-butyllithium; In hexane;	5-Methylthio-2-bromopyridine. (step 1) To a solution of 2,5-dibromopyridine (23.4 g, 0.099 mol) in ether (500 mL), n-BuLi (1.52 M in n-hexane, 68 mL, 0.10 mmol) was added dropwise at -78 C. and the mixture was stirred for 1 hour at the temperature. Dimethyldisulfide (9.8 mL, 0.11 mol) was added slowly at -78 C. and the mixture was stirred for 1 hour at that temperature and further 1 hour at 0 C. The mixture was quenched with aqueous 1N HCl (200 mL) and extracted with ether (100 mL*2), dried over magnesium sulfate (MgSO4), and concentrated in vacuo gave the title compound (18.9 g, 94%). 1H-NMR (CDCl3) δ: 8.24 (dd, J=0.8, 2.5 Hz, 1H), 7.43 (dd, J=2.8, 8.4 Hz, 1H), 7.38 (dd, J=0.8, 8.4 Hz, 1H), 2.50 (s, 3H).
94%	With hydrogenchloride; n-butyllithium; In hexane;	STEP 1 5-Methylthio-2-bromopyridine To a solution of 2,5-dibromopyridine (23.4 g, 0.099 mol) in ether (500 mL), was added dropwise n-butyl lithium (n-BuLi) (1.52 M in n-hexane, 68 mL, 0.10 mmol) at -78 C. and the mixture was stirred for 1 hour at the temperature. Dimethyldisulfide (9.8 mL, 0.11 mol) was added slowly at -78 C. and the mixture was stirred for 1 hour at that temperature and further 1 hour at 0 C. The mixture was quenched with aqueous 1N hydrochloric acid (200 mL) and extracted with ether (100 mL*2), dried over MgSO4, and concentrated in vacuo to yield the title compound (18.9 g, 94%). 1H-NMR (CDCl3) δ: 8.24 (dd, J=0.8, 2.5 Hz, 1H), 7.43 (dd, J=2.8, 8.4 Hz, 1H), 7.38 (dd, J=0.8, 8.4 Hz, 1H), 2.50 (s, 3H).

66.7%		Step 1: Synthesis of 2-bromo-5-(methylthio)pyridine To a stirred solution of 2,5-dibromopyridine (0.4 g, 1.688 mmol) in diethyl ether (15 mL) at -78 C. was added n-Butyl lithium (2.5M in hexane) (0.8 mL, 2.026 mmol) under nitrogen and stirred for 1 h at same temperature. Solution of DMDS (1.3 mL, 16.463 mmol) in diethyl ether was then added drop wise to the reaction mixture, stirred for 1 h at -78 C. and for 1 h at RT. Progress of reaction was monitored by TLC. After reaction completion reaction mass was quenched with 1N HCl and extracted with diethyl ether. The organic layer was washed with brine, dried over sodium sulphate and concentrated under reduced pressure. Crude was purified by silica gel (100-200 mesh) column chromatography using 2% ethyl acetate in hexane as eluent to obtain 2-bromo-5-(methylthio)pyridine (0.23 g, 66.7%) as yellow oil. MS: 205.0 [M++1]
		Example 1 : This example illustrates the preparation of 3-chloro-4-(3,5-dichloro-pyridin-2-yl)- 6-methyl-5-(5-methylsulfanyl-pyridin-2-yl)-pyridazine (Compound No. I. u.008); a) Preparation of 2-bromo-5-methylsulfanyl-pyridine; n-Butyllithium (1.6 M in hexane, 32 ml) is added dropwise to the solution of 2,5-dibromo- pyridine (10 g) in 100 ml of diethyl ether at -75 C under a nitrogen atmosphere. After stirring for 1 h at -75 0C, dimethyl disulfide (5 g) is added and stirring is continued for 1 h. Subsequently 50 ml of 1 N hydrochloric acid are added at - 20 0C, the reaction mixture is poured into water and extracted with ethyl acetate. The combined organic layer is washed with brine, dried over sodium sulfate and evaporated under reduced pressure. 2-bromo-5- methylsulfanyl-pyridine is obtained as a brown solid, which is used in the next step without further purification.
		Preparation Example 8: Synthesis of 2-bromo-5-methylsulfanyl-pyr idineUnder a nitrogen atmosphere, in a 500ml flask, 12g of 2,5-dibromo- pyridine and 250ml of ether were placed. At -78C 34ml of n-butyl lithium (1.52M in n-hexane) was added thereto, and after 1 hour, 4.9ml of dimethyldisulf ide was dropped. After 12-hours of stirring at room temperature, distilled water was slowly dropped at 0C and the resultant mixture was extracted with 200ml of ethyl acetate. The extract was washed with 200ml of 1N-HC1, and the organic layer was dried with anhydrous magnesium sulfate, and vacuum-dried, so as to provide a target compound.<173> ¾ NMR (400MHz, CDC13): 8.25C1H, s), 7.38-7.44(2H, m), 2.5K3H, s).
86.8 mg		A solution of 2,5-dibromopyridine (1 g, 4.22 mmol, 1 eq) in THF (20 mL) was cooled to -78 C under N2. Then, n-BuLi (2.5 M, 1.77 mL, 4.43 mmol, 1.05 eq) was added dropwise at -78 C. The reaction mixture was stirred for 20 minutes, followed by the slow addition of 1,2-dimethyldisulfane (0.411 mL, 4.64 mmol, 1.1 eq). The reaction mixture was stirred for another 1 hour before quenched by saturated NH4CI. The reaction mixture was extracted with EA (100 mL) and water (100 mL), and then washed with brine. The organic phase was dried over anhydrous NasSCL. The mixture was filtered and concentrated under reduced pressure. The crude residue was purified by flash chromatography on silica gel (PE: EA = 10: 1) to give 416 (86.8 mg): ESI [M+H]+ = 204.1 NMR (400 MHz, CDCb) d 8.25 (t, J = 6.2 Hz, 1H), 7.41 (ddd, = 8.9, 8.3, 1.6 Hz, 2H), 2.58 - 2.40 (m, 3H).
86.8 mg		A solution of 2,5-dibromopyridine (1 g, 4.22 mmol, 1 eq) in THF (20 mL) was cooled to -78 C under N2. Then, n-BuLi (2.5 M, 1.77 mL, 4.43 mmol, 1.05 eq) was added dropwise at -78 C. The reaction mixture was stirred for 20 minutes, followed by the slow addition of 1,2- dimethyldisulfane (0.411 mL, 4.64 mmol, 1.1 eq). The reaction mixture was stirred for another 1 hour before quenched by saturated MLCl. The reaction mixture was extracted with EA (100 mL) and water (100 mL), and then washed with brine. The organic phase was dried over anhydrous NasSCL. The mixture was filtered and concentrated under reduced pressure. The crude residue was purified by flash chromatography on silica gel (PE: EA = 10: 1) to give 416 (86.8 mg): ESI [M+H]+ = 204.1 NMR (400 MHz, CDCh) d 8.25 (t, J = 6.2 Hz, 1H), 7.41 (ddd, J = 8.9, 8.3, 1.6 Hz, 2H), 2.58 - 2.40 (m, 3H)
		Under nitrogen protection, to a solution of 2,5-dibromopyridine (8.34 g ,35.2 mmol) in anhydrous Et20 (200 mL) at -78 C was added n-BuLi (23.2 mL, 37 mmol) drop wise over 20 min. After the resulting mixture was stirred at -78 C for 1 hr, dimethyl disulfide (3.65 g, 38.7 mmol) was added dropwise to the reaction over 10 min. The reaction was continued to stir at -78 C for additional 1 hr. After the reaction was completed as indicated by TLC analysis, the reaction was warmed to 0 C and quenched with a diluted HC1 solution (40 mL, IN) and extracted with MTBE (100 mL x 2). The combined organic phase was washed with water (20 mL), dried and concentrated to afford 6.035 g of the crude product, which was used for the next step without further purification. LC-MS (ESI+): m/z 204, 206 (M+H)+.

References: [1]Bioorganic and Medicinal Chemistry Letters,2004,vol. 14,p. 95 - 98.
[2]Bioorganic and Medicinal Chemistry,2005,vol. 13,p. 1805 - 1809.
[3]Patent: US2002/58681,2002,A1 .
[4]Patent: US6506779,2003,B1 .
[5]Patent: US6531492,2003,B1 .
[6]Patent: US2017/291910,2017,A1 .Location in patent: Paragraph 0607-0609.
[7]Patent: WO2008/9405,2008,A2 .Location in patent: Page/Page column 16.
[8]Patent: WO2012/11707,2012,A2 .Location in patent: Page/Page column 18-19.
[9]Patent: WO2020/150474,2020,A1 .Location in patent: Page/Page column 184-185.
[10]Patent: WO2020/150473,2020,A2 .Location in patent: Page/Page column 180.
[11]Patent: WO2021/188938,2021,A1 .Location in patent: Paragraph 0701-0702.

3
[ 134872-23-4 ]
[ 343262-51-1 ]

Yield	Reaction Conditions	Operation in experiment
96%	With sodium sulfate; 3-chloro-benzenecarboperoxoic acid; In dichloromethane;	5-Methylsulfonyl-2-bromopyridine. (step 2) To a solution of 5-methylthio-2-bromopyridine from step 1 (18.9 g, 0.093 mol) in methylene chloride (600 mL), m-chloroperbenzoic acid (48 g, 0.19 mol) was added portionwise at 0 C. and the mixture was stirred for 2 hours at room temperature. Aqueous saturated Na2SO3 (200 mL) was added and stirred for 15 minutes and organic phase was separated and washed with aqueous saturated sodium bicarbonate (NaHCO3) (200 mL), dried over magnesium sulfate (MgSO4), and concentrated in vacuo gave the title compound (20.9 g, 96%). 1H-NMR (CDCl3) δ: 8.91 (d, J=2.6 Hz, 1H), 8.06 (dd, J =2.6, 8.4 Hz, 1H), 7.73 (d, J=8.4 Hz, 1H), 3.12 (s, 3H).
96%	With sodium sulfate; 3-chloro-benzenecarboperoxoic acid; In dichloromethane;	5-Methylsulfonyl-2-bromopyridine. (step 2) To a solution of 5-methylthio-2-bromopyridine from step 1 (18.9 g, 0.093 mol) in methylene chloride (600 mL), m-chloroperbenzoic acid (48 g, 0.19 mol) was added portionwise at 0 C. and the mixture was stirred for 2 hours at room temperature. Aqueous saturated Na2SO3 (200 mL) was added and stirred for 15 minutes and organic phase was separated and washed with aqueous saturated sodium bicarbonate (NaHCO3) (200 mL), dried over magnesium sulfate (MgSO4), and concentrated in vacuo gave the title compound (20.9 g, 96%). 1H-NMR (CDCl3) δ: 8.91 (d, J=2.6 Hz, 1H), 8.06 (dd, J=2.6, 8.4 Hz, 1H), 7.73 (d, J=8.4 Hz, 1H), 3.12 (s, 3H).
71%	With 3-chloro-benzenecarboperoxoic acid; In dichloromethane; at 0 - 20℃; for 2h;	Intermediate 21; 2-Bromo-5-mcthancsulfonylpyridinc; To a solution of <strong>[134872-23-4]2-bromo-5-methylsulfanylpyridine</strong> (1.53g, 7.6 mmol) in DCM (2OmL) at 0 0C was added wCPBA (3.95g, 15.95 mmol) portionwise. The mixture was allowed to warm to rt and stir for 2h. DCM (30ml) was added and the organics washed with saturated Na2SO3 solution, saturated Na2CO3 solution, dried (MgSO4) and the solvent removed in vacuo. The crude product was triturated with Et2O, filtered and dried in vacuo to afford the title compound (1.25g, 71%): δϖ (CDCl3) 3.15 (3H, s), 7.75 (IH, d), 8.08 (IH, dd), 8.95 (IH, d).

With Oxone; In tetrahydrofuran; water; at 0 - 20℃; for 3h;Inert atmosphere;

174> Preparation Example 9:Synthesis of 2-bromo-5-methanesulfonyl -pyridine<i76> Under a nitrogen atmosphere, in a 500ml flask, 5g of 5-methylthio~2- bromopyr idine was added in THF 200mL/dist i 1 led water 40mL, and stirred. At 0 C 40g of oxone was added thereto, followed by stirring at room temperature for 3 hours. Then, the reaction mixture was filtered, and the filtrate was extracted with 200ml of distilled water and 200ml of ethyl acetate. The organic layer was dried with anhydrous magnesium sulfate, and vacuum-dried so as to provide a target compound.<i77> ¾ NMR (400MHz, CDC13): 8.93(1H, s), 8.06-8.09UH, d), 7.73-7.75UH, d) ,3.14C3H, s).

References: [1]Patent: US2002/58681,2002,A1 .
[2]Patent: US6506779,2003,B1 .
[3]Bioorganic and Medicinal Chemistry Letters,2004,vol. 14,p. 95 - 98.
[4]Bioorganic and Medicinal Chemistry,2005,vol. 13,p. 1805 - 1809.
[5]Patent: WO2007/3964,2007,A1 .Location in patent: Page/Page column 53.
[6]Patent: WO2012/11707,2012,A2 .Location in patent: Page/Page column 19.

4
[ 18794-33-7 ]
[ 884863-17-6 ]
[ 134872-23-4 ]

References: [1]Tetrahedron,2006,vol. 62,p. 6036 - 6041.

5
[ 956137-23-8 ]
[ 134872-23-4 ]
(4-{4-[5-(5-methylsulfanyl-pyridin-2-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid methyl ester [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With caesium carbonate;tris-(dibenzylideneacetone)dipalladium(0); 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene; In 1,4-dioxane; at 80℃; for 18h;Sealed vessel;	2-Bromo-5-methylsulfanyl-pyridiϖe (51 mg, 0.25 mmol) and {4-[4-(5-Amino-pyridin-2-yl)- phenyl]-cyclohexyl}-acetic acid methyl ester (75 mg, 0.25 mmol) were dissolved in 1 ,4- dioxane (2 mL) in a pressure vessel. Pd2dba3 (7 mg, 0.008 mmol) and XANTPHOS (6 mg, 0.01 mmol) were added, followed by cesium carbonate (163 mg, 0.50 mmol). The mixture was sparged with nitrogen for 10 minutes, then the vessel was sealed and heated at 800C for 18 hours. The mixture was partitioned between EtOAc and water, then the organic layer was washed with brine, dried with magnesium sulfate, filtered, and concentrated via rotary evaporation. The crude material was used in the next step without further purification; MS (M+H)+ 448.3.

References: [1]Patent: WO2007/126957,2007,A2 .Location in patent: Page/Page column 122.

6
[ 134872-23-4 ]
[ 343629-25-4 ]

References: [1]Bioorganic and Medicinal Chemistry,2005,vol. 13,p. 1805 - 1809.

7
[ 134872-23-4 ]
2-Hydrazino-5-(methylsulfonyl)pyridine hydrochloride [ No CAS ]

References: [1]Bioorganic and Medicinal Chemistry,2005,vol. 13,p. 1805 - 1809.

8
[ 134872-23-4 ]
[ 343629-61-8 ]

References: [1]Bioorganic and Medicinal Chemistry Letters,2006,vol. 16,p. 2076 - 2080.
[2]Bioorganic and Medicinal Chemistry Letters,2004,vol. 14,p. 95 - 98.

9
[ 134872-23-4 ]
[ 472962-18-8 ]

References: [1]Tetrahedron,2002,vol. 58,p. 6413 - 6432.

10
[ 134872-23-4 ]
(1S,3S,7S,10R,11S,12S,16R)-7,11-Dihydroxy-8,8,10,12,16-pentamethyl-3-[(E)-1-methyl-2-(5-methylsulfanyl-pyridin-2-yl)-vinyl]-4-oxa-bicyclo[14.1.0]heptadecane-5,9-dione [ No CAS ]

References: [1]Tetrahedron,2002,vol. 58,p. 6413 - 6432.

11
[ 134872-23-4 ]
[ 472962-30-4 ]

References: [1]Tetrahedron,2002,vol. 58,p. 6413 - 6432.

12
[ 134872-23-4 ]
(1S,3R,7S,10R,11S,12S,16R)-7,11-Bis-(tert-butyl-dimethyl-silanyloxy)-8,8,10,12,16-pentamethyl-3-[(E)-1-methyl-2-(5-methylsulfanyl-pyridin-2-yl)-vinyl]-4-oxa-bicyclo[14.1.0]heptadecane-5,9-dione [ No CAS ]

References: [1]Tetrahedron,2002,vol. 58,p. 6413 - 6432.

13
[ 134872-23-4 ]
[ 472962-23-5 ]

References: [1]Tetrahedron,2002,vol. 58,p. 6413 - 6432.

14
[ 134872-23-4 ]
(3S,6R,7S,8S)-3,7-Bis-(tert-butyl-dimethyl-silanyloxy)-11-{(1R,2S)-2-[(E)-2-hydroxy-3-methyl-4-(5-methylsulfanyl-pyridin-2-yl)-but-3-enyl]-1-methyl-cyclopropyl}-4,4,6,8-tetramethyl-5-oxo-undecanoic acid 2-trimethylsilanyl-ethyl ester [ No CAS ]

References: [1]Tetrahedron,2002,vol. 58,p. 6413 - 6432.

15
(1-etoxvinyl) tributyl tin [ No CAS ]
[ 134872-23-4 ]
[ 667882-37-3 ]

Yield	Reaction Conditions	Operation in experiment
		[1-(5-METHVLSULFANYI-PVRIDIN-2-YL)-ETHANONE] To a stirring solution of 2-bromo 5-methylsulfanyl pyridine (3.05g 14. [9MMOL),] triethylamine (2. [10ML,] 14. 9mmol) and [(1-ETHOXYVINYL)] tributyl tin (10. 1mL, 29. 8mmol) in anhydrous 1,4-dioxane [(100ML),] was added dichlorobis (triphenylphosphine) palladium (II) (5mol%, 0.524g) and the reaction heated to reflux under nitrogen for 18 hours. After cooling, dichlorobis [(TRIPHENYLPHOSPHINE) PALLADIUM (II)] was added and the reaction heated under nitrogen for a further 18 hours. The reaction was allowed to cool and-the reaction mixture partitioned between saturated aqueous potassium fluoride solution (250mL) and diethyl ether (250mL). The ether layer was separated and 2N hydrochloric acid (250mL) added. The acid layer was separated and sodium carbonate added portionwise until the solution reached pH 8. The solution was extracted with [DICHLOROMETHANE] (3 x 200mL). The organic extracts were combined and the solvent removed. The residue was partitioned between cyclohexane (60ml) and acetonitrile (60mL). The acetonitrile layer was separated and the solvent removed to yield a brown solid. The crude product was purified by flash column chromatography (cyclohexane : ethyl acetate, 95: 5) to afford the title compound as a white solid : [1H] NMR [(CDCB)-ã2.] 56 (s, 3H), 2.69 (s, 3H), 7.60 (dd, 1 H), 7.96 (d, 1 H), 8.49 (d, 1H).

References: [1]Patent: WO2004/18452,2004,A1 .Location in patent: Page 19-20.

16
sodium sulfate (Na₂SO₃) [ No CAS ]
[ 134872-23-4 ]
[ 343262-51-1 ]

Yield	Reaction Conditions	Operation in experiment
96%	With 3-chloro-benzenecarboperoxoic acid; In dichloromethane;	STEP 2 5-Methylsulfonyl-2-bromopyridine To a solution of 5-methylthio-2-bromopyridine from step 1 (18.9 g, 0.093 mol) in methylene chloride (600 mL), was added portionwise m-chloroperbenzoic acid (48 g, 0.19 mol) at 0 C. and the mixture was stirred for 2 hours at room temperature. Aqueous saturated sodium sulfate (Na2SO3) (200 mL) was added and stirred for 15 minutes and organic phase was separated and washed with aqueous saturated sodium bicarbonate (NaHCO3) (200 mL), dried over MgSO4, and concentrated in vacuo gave the title compound (20.9g, 96%). 1H-NMR (CDCl3) δ: 8.91 (d, J=2.6 Hz, 1H), 8.06 (dd, J=2.6, 8.4 Hz, 1H), 7.73 (d, J=8.4 Hz, 1H), 3.12 (s, 3H).

References: [1]Patent: US6531492,2003,B1 .

17
[ 624-28-2 ]
[ 29786-93-4 ]
[ 624-92-0 ]
[ 134872-23-4 ]

Yield	Reaction Conditions	Operation in experiment
		2-Bromo [5-METHYLSULFANYL] pyridine A stirring suspension of 2, 5-dibromopyridine [(10G,] 0. [042MOL)] in anhydrous diethyl ether (240mL) was cooled to-78C under nitrogen before the dropwise addition of n-butyl lithium (1.6M in hexanes, 0. [044MOL,] 27.5mL). The reaction was stirred at-78C for 4 hours before the dropwise addition of methyl disulphide (0. [044MOL,] 3.91 mL). The reaction was allowed to warm to [22C] and stirred for a further 18 hours. The reaction was quenched with water [(100ML)] and the aqueous and organic layers partitioned. The aqueous layer was extracted with diethyl ether (x3). The extracts were combined with the organic layer, washed with brine, dried [(MGS04)] and the solvent removed. The crude product was purified by crystallisation from diethyl ether [AT-20C] to afford the title compound as a white solid [: H] NMR [(CDC . A)-52.] 50 (s, 3H), 7.38 (dd, 1 H), 7.42 (dd, 1H), 8.23 (d, [1H).]

References: [1]Patent: WO2004/18452,2004,A1 .Location in patent: Page 19.

18
[ 107-12-0 ]
[ 134872-23-4 ]
[ 1002760-15-7 ]

Yield	Reaction Conditions	Operation in experiment
		b) Preparation of 1-(5-methylsulfanyl-pyridin-2-yl)-propan-1-one; n-Butyllithium (1.6 M in hexane, 30 ml) is added dropwise to the solution of 2-bromo-5- methylsulfanyl-pyridine (8.1 g) in 370 ml of toluene at -75 0C under a nitrogen atmosphere. After stirring for 2 h at -75 0C, propionitrile (2.8 g) is added and stirring is continued for 1 h. Subsequently, 60 ml of 1 N hydrochloric acid are slowly added at -10 0C and the reaction <n="18"/>mixture is neutralised with 2 N NaOH. The reaction mixture is poured into water, extracted with ethyl acetate, washed with brine, dried over sodium sulfate and evaporated under reduced pressure. The remainder is purified on silica gel, using a mixture of heptane / ethyl acetate 9 : 1 as eluent to obtain 1-(5-methylsulfanyl-pyridin-2-yl)propan-1-one as a yellow solid (m.p. 52 - 53 0C).

References: [1]Patent: WO2008/9405,2008,A2 .Location in patent: Page/Page column 16-17.

19
C₂₁H₂₀Cl₂N₂ [ No CAS ]
[ 134872-23-4 ]
C₂₇H₂₅Cl₂N₃S [ No CAS ]

References: [1]Journal of Medicinal Chemistry,2009,vol. 52,p. 5323 - 5329.

20
[ 95-92-1 ]
[ 134872-23-4 ]
[ 1080061-07-9 ]

Yield	Reaction Conditions	Operation in experiment
43%		Reference Example 144 ethyl [5-(methylsulfanyl)pyridin-2-yl](oxo)acetate A solution of n-butyllithium (1.6M hexane solution, 10.6 mL) in toluene (10 mL) was cooled to -45C and purged with nitrogen. n-Butylmagnesium chloride (2.0M tetrahydrofuran solution, 4.22 mL) was added dropwise to the reaction mixture, and the mixture was stirred at 0C for 30 min. To the reaction mixture was added dropwise a solution of 2-bromo-5-(methylsulfanyl)pyridine (4.30 g) in toluene (40 mL), and the mixture was stirred at -20C for 2.5 hr. To the reaction mixture was added diethyl oxalate (4.29 mL), and the mixture was stirred at room temperature for 24 hr. A saturated aqueous ammonium chloride solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The extract was washed with saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was subjected to silica gel column chromatography, and the title compound (2.05 g, yield 43%) was obtained as a yellow amorphous solid from a fraction eluted with ethyl acetate-hexane (1:2, volume ratio). 1H NMR (300 MHz, CDCl3) δ1.41 (3 H, t, J=7.2 Hz), 2.58 (3 H, s), 4.47 (2 H, q, J=7.2 Hz), 7.64 (1 H, dd, J=2.4, 8.3 Hz), 7.97 - 8.03 (1 H, m), 8.54 (1 H, d, J=2.3 Hz).

References: [1]Patent: EP2149550,2010,A1 .Location in patent: Page/Page column 111-112.

21
[ 64-17-5 ]
[ 201230-82-2 ]
[ 134872-23-4 ]
[ 128073-11-0 ]

Yield	Reaction Conditions	Operation in experiment
91%	With 1,3-bis-(diphenylphosphino)propane; triethylamine;palladium diacetate; In N,N-dimethyl-formamide; at 70℃; for 4h;	A mixture of 2-bromo-5- (methylthio) pyridine (5.41 g) , palladium (II) acetate (0.60 g) , 1,3- bis (diphenylphosphino) propane (1.37 g) , triethylamine (18.5 mL) , ethanol (30 mL) and N, N-dimethylformamide (30 mL) was stirred for 4 hrs at 700C under carbon monooxide atmosphere. The reaction mixture was concentrated, water was added, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate: hexane = 1:1) to give the title compound (4.73 g, yield 91%) as yellow crystals. Melting point 44-46C.

References: [1]Patent: WO2008/156757,2008,A1 .Location in patent: Page/Page column 211.

22
[ 134872-23-4 ]
[ 1093967-05-5 ]

References: [1]Patent: WO2008/156757,2008,A1 .

23
[ 134872-23-4 ]
[ 1093967-06-6 ]

References: [1]Patent: WO2008/156757,2008,A1 .

24
[ 134872-23-4 ]
[ 1439378-81-0 ]

References: [1]Journal of Organic Chemistry,2013,vol. 78,p. 6344 - 6349.

25
2-methyl-2-nitrosopropane dimer [ No CAS ]
[ 134872-23-4 ]
[ 1439378-73-0 ]

References: [1]Journal of Organic Chemistry,2013,vol. 78,p. 6344 - 6349.

26
[ 5334-35-0 ]
[ 134872-23-4 ]
1-methyl-6-(5-methylsulfonyl-2-pyridyl)-5H-pyrazolo[3,4-d]pyrimidin-4-one [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
		Example 111 1- methyl-6-(5-methylsulfonyl-2-pyridyl)-5H-pyrazolo[3 4-d]pyrimidin-4-one 2- Bromo-5-(methylthio)-pyridine (CASRN 134872-23-4) is converted to an organozinc compound (n-BuLi, ZnCl2) and condensed with Intermediate A (Pd2(dpa)3/dppf) and the resulted adducted oxidized to the corresponding sulfone (MCPBA) to afford the title compound: H NMR (400 MHz, DMSO-i δ ppm 11.95 (s, 1H), 9.22 (d, J = 1.6 Hz, 1H), 8.67 (d, J = 8.0 Hz, 1H), 8.58 (dd, J = 8.4 Hz, J = 2.4Hz, 1H), 8.16 (s, 1H), 4.03 (s, 3H), 3.44 (s, 3H).

References: [1]Patent: WO2013/182546,2013,A1 .Location in patent: Page/Page column 142.

27
[ 134872-23-4 ]
2-bromo-5-(S-methylsulfinyl)pyridine [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With sodium periodate; acetic acid; In water; at 20℃; for 2h;	Step 1: 2-Bromo-S-methylsulfinyl-pyridine A mixture of 2-bromo-S-methylsulfanyl-pyridine (8.67 g), sodium periodate (12.72 g), concentrated acetic acid (115 mL), and water (30 μL) is stirred at room temperature for 2 h. The reaction mixture is diluted with water and extracted with ethyl acetate. The combined extracts are washed with sodium thiosulfate (10% aqueous solution), potassium carbonate (10% aqueous solution), and brine, dried over MgSO4 and concentrated in vacuo. The crude product is used for the next reaction step without further purification. LC (method 3): tR=0.57 min; Mass spectrum (ESI+): m/z=220 [M+H]+.
	With sodium periodate; acetic acid; In water; at 20℃; for 2h;	A mixture of 2-bromo-5-methylsulfanyl-pyridine (8.67 g), sodium periodate (12.72 g), concentrated acetic acid (1 15 mL), and water (30 μΙ_) is stirred at room temperature for 2 h. The reaction mixture is diluted with water and extracted with ethyl acetate. The combined extracts are washed with sodium thiosulfate (10 % aqueous solution), potassium carbonate (10 % aqueous solution), and brine, dried over MgS04 and concentrated in vacuo. The crude product is used for the next reaction step without further purification. LC (method 3): tR = 0.57 min; Mass spectrum (ESI): m/z = 220 [M+H]+

References: [1]Patent: US2015/25065,2015,A1 .Location in patent: Paragraph 0299-0300.
[2]Patent: WO2015/7669,2015,A1 .Location in patent: Page/Page column 70.

28
[ 134872-23-4 ]
2-(4-bromophenyl)-5-(S-methylsulfinyl)pyridine [ No CAS ]

References: [1]Patent: US2015/25065,2015,A1 .
[2]Patent: WO2015/7669,2015,A1 .

29
[ 134872-23-4 ]
2-(4-bromophenyl)-5-(N-(2,2,2-trifluoroacetyl)-S-methylsulfonimidoyl)pyridine [ No CAS ]

References: [1]Patent: US2015/25065,2015,A1 .
[2]Patent: WO2015/7669,2015,A1 .

30
[ 134872-23-4 ]
2-(4-bromophenyl)-5-(S-methylsulfonimidoyl)pyridine [ No CAS ]

References: [1]Patent: US2015/25065,2015,A1 .
[2]Patent: WO2015/7669,2015,A1 .

31
[ 134872-23-4 ]
2-(1-(1-(3-isopropyl-1,2,4-oxadiazol-5-yl)piperidin-4-yl)ethoxy)-5-(5-(methylthio)pyridin-2-yl)thiazolo[5,4-b]pyridine [ No CAS ]

References: [1]Patent: US2017/291910,2017,A1 .

32
[ 134872-23-4 ]
2-(1-(1-(3-isopropyl-1,2,4-oxadiazol-5-yl)piperidin-4-yl)ethoxy)-5-(5-(methylsulfonyl)pyridin-2-yl)thiazolo[5,4-b]pyridine [ No CAS ]

References: [1]Patent: US2017/291910,2017,A1 .

33
[ 1461-22-9 ]
[ 134872-23-4 ]
2-(tributylstannyl)-5-(methylthio)pyridine [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
55.67%		Step 2: Synthesis of 2-(tributylstannyl)-5-(methylthio)pyridine To a stirred solution of 2-bromo-5-(methylthio)pyridine (0.23 g, 1.127 mmol) in diethyl ether (15 mL) at -78 C. was added n-Butyl lithium (2.5M in hexane) (0.67 mL, 1.691 mmol) under nitrogen and stirred for 1 h at same temperature. Tributylchlorostannane (0.55 g, 1.691 mmol) was then added drop wise to the reaction mixture, stirred for 1 h at -78 C. and for 2 h at RT. Progress of reaction was monitored by TLC. After reaction completion reaction mass was quenched with water and extracted with diethyl ether. The organic layer was washed with brine, dried over sodium sulphate and concentrated under reduced pressure to obtain 2-(tributylstannyl)-5-(methylthio)pyridine (0.26 g, 55.67%) as yellow oil. MS: 415.2 [M++1]

References: [1]Patent: US2017/291910,2017,A1 .Location in patent: Paragraph 0610-0612.

34
C₁₄H₁₇N₅O [ No CAS ]
[ 134872-23-4 ]
2-(6-(((1S,3S)-3-((5-(methylthio)pyridin-2-yl)amino)cyclopentyl)amino)pyridin-3-yl)pyridazin-3(2H)-one [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With [(2-di-tert-butylphosphino-2′,4′,6′-triisopropyl-1, 1′-biphenyl)-2-(2′-amino-1,1′-biphenyl)] palladium(II) methanesulfonate; potassium tert-butylate; In 1,4-dioxane; at 110℃;Inert atmosphere;	General procedure: The mixture of 400A (53 mg, 0.22 mmol, 1.0 eq), 131C (50 mg, 0.22 mmol. 1.0 eq), tBuXphos Pd G3 (18 mg, 0.022 mmol, 0.1 eq) and tBuOK (49 mg, 0.44 mmol, 0.2 eq) in dioxane (5 mL) was stirred at 110 C under N2 atmosphere overnight. The mixture was cooled to room temperature and filtered. The filtrate was concentrated and purified by Prep-TLC and then Prep-HPLC to afford compound 400 (50 mg, 53%, TFA salt) as an off-white solid.

References: [1]Patent: WO2020/150473,2020,A2 .Location in patent: Page/Page column 222.

Historical Records

Technical Information

• Alkyl Halide Occurrence • General Reactivity • Grignard Reaction • Hiyama Cross-Coupling Reaction • Hydride Reductions • Kinetics of Alkyl Halides • Kumada Cross-Coupling Reaction • Nucleophilicity of Sulfur Compounds • Oxidation States of Sulfur Compounds • Preparation of Amines • Reactions of Alkyl Halides with Reducing Metals • Reactions of Amines • Reactions of Dihalides • Stille Coupling • Substitution and Elimination Reactions of Alkyl Halides • Suzuki Coupling

Related Functional Groups of
[ 134872-23-4 ]

Bromides

A923681 [884863-17-6]

2-Bromo-3-(methylthio)pyridine

Similarity: 0.91

A262286 [70682-11-0]

2-Bromo-3-((trifluoromethyl)thio)pyridine

Similarity: 0.83

A703725 [1193244-96-0]

2-Bromo-5-(methylsulfinyl)pyridine

Similarity: 0.83

Sulfides

A923681 [884863-17-6]

2-Bromo-3-(methylthio)pyridine

Similarity: 0.91

A262286 [70682-11-0]

2-Bromo-3-((trifluoromethyl)thio)pyridine

Similarity: 0.83

Related Parent Nucleus of
[ 134872-23-4 ]

Pyridines

A923681 [884863-17-6]

2-Bromo-3-(methylthio)pyridine

Similarity: 0.91

A262286 [70682-11-0]

2-Bromo-3-((trifluoromethyl)thio)pyridine

Similarity: 0.83

A703725 [1193244-96-0]

2-Bromo-5-(methylsulfinyl)pyridine

Similarity: 0.83

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed
H304	May be fatal if swallowed and enters airways
H305	May be harmful if swallowed and enters airways
H310	Fatal in contact with skin
H311	Toxic in contact with skin
H312	Harmful in contact with skin
H313	May be harmful in contact with skin
H314	Causes severe skin burns and eye damage
H315	Causes skin irritation
H316	Causes mild skin irritation
H317	May cause an allergic skin reaction
H318	Causes serious eye damage
H319	Causes serious eye irritation
H320	Causes eye irritation
H330	Fatal if inhaled
H331	Toxic if inhaled
H332	Harmful if inhaled
H333	May be harmful if inhaled
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled
H335	May cause respiratory irritation
H336	May cause drowsiness or dizziness
H340	May cause genetic defects
H341	Suspected of causing genetic defects
H350	May cause cancer
H351	Suspected of causing cancer
H360	May damage fertility or the unborn child
H361	Suspected of damaging fertility or the unborn child
H361d	Suspected of damaging the unborn child
H362	May cause harm to breast-fed children
H370	Causes damage to organs
H371	May cause damage to organs
H372	Causes damage to organs through prolonged or repeated exposure
H373	May cause damage to organs through prolonged or repeated exposure
Environmental hazards
Code	Phrase
H400	Very toxic to aquatic life
H401	Toxic to aquatic life
H402	Harmful to aquatic life
H410	Very toxic to aquatic life with long-lasting effects
H411	Toxic to aquatic life with long-lasting effects
H412	Harmful to aquatic life with long-lasting effects
H413	May cause long-lasting harmful effects to aquatic life
H420	Harms public health and the environment by destroying ozone in the upper atmosphere

{[proInfo.proName]}

CAS No.: 134872-23-4

{[proInfo.proName]}